NET-1、Ki67和CD34在胃癌组织中的表达 及其临床病理意义

 目的探讨胃癌组织中NET-1、Ki67和CD34表达的临床病理学意义。方法应用免疫组化二步法检测86例胃癌组织中NET-1、Ki67和CD34的表达，对三指标均阳性病例进行免疫组化三重标记法双染方法，原位检测三指标的表达特点和毗邻关系。所有病例随访60月以上。结果胃癌组织中 NET-1、Ki67和CD34高表达分别为56.98%、74.42%和62.79%，三指标阳性表达呈显著正相关（P<0.01）。三指标高表达分别与肿瘤临床分期呈正相关（均P<0.05），与患者生存率呈负相关（均P<0.05）， 其3、5年生存率均显著低于相应的低表达组或阴性组（P<0.05，P<0.01）。 NET-1、Ki67高表达分别与肿瘤分化呈负相关（均P<0.01）。NET-1、CD34高表达分别与癌浸润深度、淋巴结转移呈正相关（均P<0.05）。结论NET-1、Ki67和CD34在胃癌组织中高表达与癌细胞增殖、癌血管形成和预后差有关。

Overexpression and Clinicopathological Significance of NET-1, Ki67 and CD34 in Gastric Carcinoma

To investigate the overexpression of NET-1、Ki67 and CD34 and clinicopathological significance in gastric carcinoma.MethodsThe overexpression of NET-1、Ki67 and CD34 was detected in 86 cases of gastric carcinoma paraffin-embeded sections by immunohistochemical method. Immunohistochemical trimarkers double staining method was used to detect all positive cases with the three markers and show the adjacent relationship and accompanying conditions between NET-1、Ki67 and CD34 on the one slide.All cases were followed up over 60 months.ResultsThe overexpression rates of NET-1, Ki67 and CD34 in gastric carcinoma were 56.98％、74.42％ and 62.79％,respectively. There was significant positive correlation between these three markers (P <0.05). The overexpression rate of these markers were remarkably positive correlated with tumor clinical stages（P<0.05）and negatively correlated with tumor survival rate（P<0.05）and metastasis （P<0.05）. The survival rate within 3 and 5 years were dramatically shorter in the overexpression groups of these three markers than that in low expression groups and the negative groups（P<0.05，P<0.01） . The overexpression of NET-1 and Ki67 were negatively correlated with carcinoma differentiation (P<0.01). The overexpression of NET-1 and CD34 was positively correlated with infiltration and lymph node status of tumor (P<0.05), respectively.ConclusionThe overexpression of NET-1, Ki67 and CD34 proteins was related with the proliferation, angiogenesis and poor prognosis in gastric carcinoma.